METHODS Subjects Thirty-two healthy male volunteers were
... For the purposes of this study, we developed a new database of face stimuli (The Oslo Face Database), consisting of color photographs of 187 young individuals (103 females). Three full-frontal view photographs were taken for each individual: one picture with direct gaze, and two pictures with averte ...
... For the purposes of this study, we developed a new database of face stimuli (The Oslo Face Database), consisting of color photographs of 187 young individuals (103 females). Three full-frontal view photographs were taken for each individual: one picture with direct gaze, and two pictures with averte ...
Therapeutic applications of ricin and some alkaloids
... moAbs that recognize different markers on Hodgkin/Reed-Sternberg (H-RS) cells, tested their antitumor activity successfully in vitro and also in mice Hodgkin’s tumor models. Therefore, they advocated its use for clinical trials in human patients with Hodgkin’s disease. To establish the efficacy of s ...
... moAbs that recognize different markers on Hodgkin/Reed-Sternberg (H-RS) cells, tested their antitumor activity successfully in vitro and also in mice Hodgkin’s tumor models. Therefore, they advocated its use for clinical trials in human patients with Hodgkin’s disease. To establish the efficacy of s ...
Pharmacology 2002
... someone with a normal heart, or normal doses to someone with a long ECG QT interval, will increase the likelihood of an arrhythmia. Drugs which reduce cisapride metabolism by inhibiting CYP3A4 (e.g. macrolides) can increase its concentration and further increase the chance of a potentially fatal arr ...
... someone with a normal heart, or normal doses to someone with a long ECG QT interval, will increase the likelihood of an arrhythmia. Drugs which reduce cisapride metabolism by inhibiting CYP3A4 (e.g. macrolides) can increase its concentration and further increase the chance of a potentially fatal arr ...
and delayed-type allergic reactions to amide local anesthetics
... Purpose Amide type local anesthetic agents are among the most commonly used drugs in medicine. Several adverse drug reactions (ADRs) have been previously described with their use. Among them, allergic reactions are considered rare. The aim of this study was to describe the main characteristics of AD ...
... Purpose Amide type local anesthetic agents are among the most commonly used drugs in medicine. Several adverse drug reactions (ADRs) have been previously described with their use. Among them, allergic reactions are considered rare. The aim of this study was to describe the main characteristics of AD ...
% 4 L Memorandum
... assume that the mean weight was 70 kg when the dose is gilren as mg/kg without body weights. In the intravenous ...
... assume that the mean weight was 70 kg when the dose is gilren as mg/kg without body weights. In the intravenous ...
Treatment of Elderly Hypertensive Patients with Angiotensin
... approximately 50% of diabetics from the general population have hypertension, with rates increasing in the elderly, for whom renal disease is a major cause of morbidity and mortality. The benefits of ACEIs in the treatment of Type 1 diabetic patients with albuminuria have been recognised for some ti ...
... approximately 50% of diabetics from the general population have hypertension, with rates increasing in the elderly, for whom renal disease is a major cause of morbidity and mortality. The benefits of ACEIs in the treatment of Type 1 diabetic patients with albuminuria have been recognised for some ti ...
Psychopharmacology Training
... potency for reuptake inhibition and affinity for some other receptors Overall, less effects on adrenergic, histaminergic and cholinergic ...
... potency for reuptake inhibition and affinity for some other receptors Overall, less effects on adrenergic, histaminergic and cholinergic ...
Classification of research and development activities
... and informal or occasional R&D in other units. The Manual also refers to Post approval activities related to pharmaceutical and biotechnological development, stating ...
... and informal or occasional R&D in other units. The Manual also refers to Post approval activities related to pharmaceutical and biotechnological development, stating ...
Titel voorbeeld titel
... Picard et al is mentioned that the effectively doses for imatinib a plasma threshold of 1000 ng/ml is considered. Routinely the method is mainly used for TDM of patients which treat with erlotinib. Based on the study of Hidalgo a plasma concentration of 500 ug/L have been estimated to provide a leve ...
... Picard et al is mentioned that the effectively doses for imatinib a plasma threshold of 1000 ng/ml is considered. Routinely the method is mainly used for TDM of patients which treat with erlotinib. Based on the study of Hidalgo a plasma concentration of 500 ug/L have been estimated to provide a leve ...
PIO Nas - Badan Pengawas Obat dan Makanan
... This property guarantees a good tolerability without bad tastes and without mercaptanic regurgitations and with good gastric tolerability. Pharmacokinetic ...
... This property guarantees a good tolerability without bad tastes and without mercaptanic regurgitations and with good gastric tolerability. Pharmacokinetic ...
london cancer networks - London Cancer Alliance
... Line of treatment: Please specify Cost of treatment (per Dose) Calculated as 1.75m2 x 375mg = 675mg, inc wastage = 700mg, +VAT @ 20% If Dose differs from above, enter revised Cost per Dose Please indicate whether the patient meets the following LCNDG CDF criteria Patient has confirmed CD20 expressio ...
... Line of treatment: Please specify Cost of treatment (per Dose) Calculated as 1.75m2 x 375mg = 675mg, inc wastage = 700mg, +VAT @ 20% If Dose differs from above, enter revised Cost per Dose Please indicate whether the patient meets the following LCNDG CDF criteria Patient has confirmed CD20 expressio ...
original article efficacy of pregabalin in immediate post
... gabapentinoids is becoming more common. Sensitization of neurons in dorsal horn, a mechanism in neuropathic pain is present in acute pain models also.12 Voltage gated calcium channels play a large role in the increase of nociceptive drive due to neuropathic as well as acute inflammatory pain. Pregab ...
... gabapentinoids is becoming more common. Sensitization of neurons in dorsal horn, a mechanism in neuropathic pain is present in acute pain models also.12 Voltage gated calcium channels play a large role in the increase of nociceptive drive due to neuropathic as well as acute inflammatory pain. Pregab ...
Pramipexole in the Management of Restless Legs Syndrome
... systematically. However, Stiasny et al12 also found only 1 of 24 patients described sleepiness in the evening related to taking a dose of the medication, and none reported “sleep attacks.” The risk of sleepiness with pramipexole, especially while driving, appears to be lower in patients with RLS tha ...
... systematically. However, Stiasny et al12 also found only 1 of 24 patients described sleepiness in the evening related to taking a dose of the medication, and none reported “sleep attacks.” The risk of sleepiness with pramipexole, especially while driving, appears to be lower in patients with RLS tha ...
Established and forthcoming drugs for the treatment of osteoporosis
... visual analogue scale at baseline was 57.7 mm, and this was reduced by 25.8 mm after 18 months of treatment (p<0.001). In addition to that, an increase in quality of life was observed. Given the fact that glucocorticoids (GC) induce apoptosis of osteoblasts and osteocytes, with a subsequent inhibiti ...
... visual analogue scale at baseline was 57.7 mm, and this was reduced by 25.8 mm after 18 months of treatment (p<0.001). In addition to that, an increase in quality of life was observed. Given the fact that glucocorticoids (GC) induce apoptosis of osteoblasts and osteocytes, with a subsequent inhibiti ...
Issuer Free Writing Prospectus dated June 20, 2016 Filed Pursuant
... After the date of the Preliminary Prospectus, a serious adverse event in the Phase 1b clinical trial of SEL-212 was observed. This serious adverse event was in addition to the two serious adverse events previously disclosed in the Preliminary Prospectus. Accordingly, the disclosures set forth on pag ...
... After the date of the Preliminary Prospectus, a serious adverse event in the Phase 1b clinical trial of SEL-212 was observed. This serious adverse event was in addition to the two serious adverse events previously disclosed in the Preliminary Prospectus. Accordingly, the disclosures set forth on pag ...
Comparability Study (for Biosimilar)
... Inconclusive data in response rate for Genotype 1 patients Different rate of adverse events Inadequate immunogenicity documentation ...
... Inconclusive data in response rate for Genotype 1 patients Different rate of adverse events Inadequate immunogenicity documentation ...
Analysis of the Acquisition of Drug Discrimination Reveals
... robust discriminative stimulus effect than the 1.5 mg/kg dose which is typically used. It must be acknowledged that the present training period was only 63 days in duration. While this was apparently sufficient for the acquisition of the high dose MDMA discrimination, it is possible that the lower d ...
... robust discriminative stimulus effect than the 1.5 mg/kg dose which is typically used. It must be acknowledged that the present training period was only 63 days in duration. While this was apparently sufficient for the acquisition of the high dose MDMA discrimination, it is possible that the lower d ...
Lieberman et al 2005
... in the quetiapine group (hazard ratio, 0.63; P<0.001), the risperidone group (hazard ratio, 0.75; P=0.002), or the perphenazine group (hazard ratio, 0.78; P=0.021) (Table 2). However, the difference between the olanzapine group and the perphenazine group was not significant after adjustment for mult ...
... in the quetiapine group (hazard ratio, 0.63; P<0.001), the risperidone group (hazard ratio, 0.75; P=0.002), or the perphenazine group (hazard ratio, 0.78; P=0.021) (Table 2). However, the difference between the olanzapine group and the perphenazine group was not significant after adjustment for mult ...
DICETEL PM
... If you have any allergies or have had a reaction to any of the ingredients in DICETEL (see What is DICETEL?). If you are lactose intolerant, talk to your doctor, as this product contains lactose. If you have been told by your doctor that you have a rare condition of intolerance to some sugars or dif ...
... If you have any allergies or have had a reaction to any of the ingredients in DICETEL (see What is DICETEL?). If you are lactose intolerant, talk to your doctor, as this product contains lactose. If you have been told by your doctor that you have a rare condition of intolerance to some sugars or dif ...
product monograph
... Use of HEMABATE STERILE SOLUTION is associated with transient pyrexia that may be due to hypothalamic thermoregulation. Fever was reported by 8 of 115 (7%) patients treated in an open-label clinical trial of patients with postpartum hemorrhage due to uterine atony who had not responded to convention ...
... Use of HEMABATE STERILE SOLUTION is associated with transient pyrexia that may be due to hypothalamic thermoregulation. Fever was reported by 8 of 115 (7%) patients treated in an open-label clinical trial of patients with postpartum hemorrhage due to uterine atony who had not responded to convention ...
Results of Some Urological Problems with Cernilton
... In 1960 Ask-Upmark (15) published a report on a patient who had been under medical treatment for chronic prostatitis since 1952 but who had begun taking pollen tablets. At a dose of 6 tablets a day, this patient experienced relief from fatigue and a disappearance of symptoms, but also recurrences of ...
... In 1960 Ask-Upmark (15) published a report on a patient who had been under medical treatment for chronic prostatitis since 1952 but who had begun taking pollen tablets. At a dose of 6 tablets a day, this patient experienced relief from fatigue and a disappearance of symptoms, but also recurrences of ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.